Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945993 | 0.91 | KMT2A (0.49) | RAB9ACASP3MAPTTP53POLB | |
| SCHEMBL7940591 | 0.85 | GAA (0.46) | CASP3MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL12230833 | 0.84 | CASP3 (0.53) | RAB9ACASP3MAPTTP53MITF | |
| SCHEMBL7947585 | 0.77 | S1PR1 (0.41) | CASP3MAPTTP53KMT2ALMNA | |
| SCHEMBL12230834 | 0.75 | G6PD (0.74) | CASP3HPGDG6PDCASP7 | |
| SCHEMBL15195144 | 0.74 | S1PR1 (0.44) | RAB9ACASP3TP53HPGDLMNA | |
| SCHEMBL7947824 | 0.72 | MAPT (0.77) | MAPTPOLBMEN1KMT2ALMNA | |
| SCHEMBL31217454 | 0.72 | MAPT (0.51) | RAB9ACASP3MAPTTP53ALDH1A1 | |
| SCHEMBL7938109 | 0.69 | TACR2 (0.63) | MITFALDH1A1POLBMAPK1HTT | |
| SCHEMBL12205849 | 0.68 | KAT2A (0.58) | CASP3G6PDCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513295-B2 | Viral and fungal inhibitors | GEORGETOWN UNIVERSITY (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513295-B2 | Viral and fungal inhibitors | GEORGETOWN UNIVERSITY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110301208-A1 | VIRAL AND FUNGAL INHIBITORS | WICHITA STATE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301208-A1 | VIRAL AND FUNGAL INHIBITORS | WICHITA STATE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010039534-A2 | VIRAL AND FUNGAL INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301208-A1 | VIRAL AND FUNGAL INHIBITORS | HAVCR2, ZC3HAV1, ERG28 | RAB9A 2396/4885CASP3 1969/4885MAPT 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.